Q2 Earnings Estimate for REGENXBIO Issued By Leerink Partnrs

REGENXBIO Inc. (NASDAQ:RGNX) – Equities researchers at Leerink Partnrs upped their Q2 2025 EPS estimates for REGENXBIO in a report issued on Monday, May 19th. Leerink Partnrs analyst M. Foroohar now anticipates that the biotechnology company will post earnings per share of ($0.89) for the quarter, up from their prior estimate of ($1.47). The consensus estimate for REGENXBIO’s current full-year earnings is ($4.84) per share. Leerink Partnrs also issued estimates for REGENXBIO’s Q3 2025 earnings at $2.60 EPS, Q4 2025 earnings at ($1.48) EPS, FY2025 earnings at $0.35 EPS, FY2026 earnings at ($1.69) EPS, FY2027 earnings at ($3.03) EPS, FY2028 earnings at ($2.22) EPS and FY2029 earnings at ($1.15) EPS.

REGENXBIO (NASDAQ:RGNX) last issued its quarterly earnings results on Monday, May 12th. The biotechnology company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.41 by ($0.29). The business had revenue of $89.01 million for the quarter, compared to analysts’ expectations of $105.35 million. REGENXBIO had a negative return on equity of 70.65% and a negative net margin of 283.19%.

Other research analysts also recently issued research reports about the stock. Chardan Capital reaffirmed a “buy” rating and set a $52.00 price objective on shares of REGENXBIO in a research note on Thursday, March 20th. Leerink Partners set a $24.00 price target on shares of REGENXBIO in a research report on Tuesday, March 18th. Morgan Stanley lifted their price target on shares of REGENXBIO from $22.00 to $24.00 and gave the company an “overweight” rating in a report on Friday, March 14th. Wall Street Zen raised shares of REGENXBIO from a “sell” rating to a “hold” rating in a research note on Friday, March 7th. Finally, Raymond James initiated coverage on REGENXBIO in a research report on Friday, February 7th. They issued an “outperform” rating and a $27.00 target price on the stock. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, REGENXBIO currently has a consensus rating of “Moderate Buy” and an average target price of $31.63.

REGENXBIO Trading Up 2.3%

NASDAQ RGNX opened at $9.86 on Thursday. The business’s 50-day moving average price is $7.78 and its 200 day moving average price is $8.01. REGENXBIO has a twelve month low of $5.04 and a twelve month high of $15.91. The company has a market capitalization of $494.58 million, a PE ratio of -1.96 and a beta of 1.11.

Institutional Investors Weigh In On REGENXBIO

Several institutional investors and hedge funds have recently modified their holdings of RGNX. Price T Rowe Associates Inc. MD lifted its position in REGENXBIO by 9.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 23,910 shares of the biotechnology company’s stock worth $185,000 after acquiring an additional 1,982 shares in the last quarter. Teacher Retirement System of Texas raised its stake in shares of REGENXBIO by 19.9% during the fourth quarter. Teacher Retirement System of Texas now owns 12,590 shares of the biotechnology company’s stock valued at $97,000 after purchasing an additional 2,088 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in shares of REGENXBIO by 9.1% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 27,756 shares of the biotechnology company’s stock worth $198,000 after purchasing an additional 2,326 shares in the last quarter. DnB Asset Management AS lifted its position in shares of REGENXBIO by 20.1% during the fourth quarter. DnB Asset Management AS now owns 14,539 shares of the biotechnology company’s stock worth $112,000 after purchasing an additional 2,434 shares in the last quarter. Finally, ProShare Advisors LLC boosted its stake in shares of REGENXBIO by 22.4% in the fourth quarter. ProShare Advisors LLC now owns 15,314 shares of the biotechnology company’s stock valued at $118,000 after purchasing an additional 2,800 shares during the period. Hedge funds and other institutional investors own 88.08% of the company’s stock.

Insider Buying and Selling

In other REGENXBIO news, Director Kenneth T. Mills sold 20,602 shares of the firm’s stock in a transaction dated Monday, May 12th. The stock was sold at an average price of $7.91, for a total value of $162,961.82. Following the transaction, the director now directly owns 475,103 shares of the company’s stock, valued at $3,758,064.73. This trade represents a 4.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 12.79% of the stock is owned by corporate insiders.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.